Genetics

Atlas Global Brands Signs LOI with a Licensed Cannabis Producer

Retrieved on: 
Thursday, January 12, 2023
THC, Seedling, Vendor, CSE, GACP, ATL, Genetics, Terpene, Interim

The final structure of the Proposed Transaction will be determined by the parties following receipt of tax, corporate and securities law advice.

Key Points: 
  • The final structure of the Proposed Transaction will be determined by the parties following receipt of tax, corporate and securities law advice.
  • The privately held Licensed Producer uses an innovative genetic selection program to search for outstanding phenotypes, enhancing its ability to achieve the full genetic potential of its cultivars.
  • With the addition of a nursery operation, the Licensed Producer has access to hundreds of genetics from around the world.
  • “This transaction demonstrates our commitment to investing in our core business, as we position Atlas as a global growth and innovation platform.

CENTOGENE and Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics

Retrieved on: 
Monday, January 9, 2023
Disease, Neurodegeneration, Safety, PD, Genetics, Biogen, Partnership, Patient, Diagnosis, Therapy, Drug discovery, HIV disease progression rates, ClinicalTrials.gov, Denali, Pharmaceutical industry, LRRK2

In 2018, CENTOGENE entered a strategic collaboration with Denali Therapeutics for the targeted global identification of PD patients with genetic variations in the LRRK2 gene.

Key Points: 
  • In 2018, CENTOGENE entered a strategic collaboration with Denali Therapeutics for the targeted global identification of PD patients with genetic variations in the LRRK2 gene.
  • CENTOGENE conducts clinical studies with pharma partners around the world, such as Denali Therapeutics.
  • “Parkinson’s disease is a devastating neurodegenerative disease – affecting over 10 million people worldwide from all walks of life.
  • There is an urgent medical need to unveil multidimensional data,” said Kim Stratton, Chief Executive Officer at CENTOGENE.

IFF’s Philippe Horvath Inducted into The National Inventors Hall of Fame

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Health, Specialty, Food, Beverage, Other Science, Cosmetics, Research, Infectious Diseases, Retail, Genetics, Science, All rights reserved, Degenerative disease, National Inventors Hall of Fame, Virus, Trademark, NYSE, Health, Franklin Institute Awards, Bacteria, Gene editing, International Flavors & Fragrances, Rodolphe Barrangou, Immune system, Creativity, Research, Massry Prize, North East of England Process Industry Cluster, Warren Alpert Foundation Prize, Canada Gairdner International Award, Horváth, Food, Vaccine, Perfume, CRISPR, D.C, Science

Philippe Horvath—renowned molecular biologist and IFF technical fellow—is being inducted into the National Inventors Hall of Fame® Class of 2023.

Key Points: 
  • Philippe Horvath—renowned molecular biologist and IFF technical fellow—is being inducted into the National Inventors Hall of Fame® Class of 2023.
  • Applying this research to enhance starter cultures in the dairy industry, Horvath and research partner Rodolphe Barrangou improved the world’s food supply and laid the foundation for the field of gene editing.
  • “We are proud of the achievements made by Philippe and the entire CRISPR team.
  • “I am deeply honored to be selected by the National Inventors Hall of Fame to represent the pioneering work our team has done,” said Horvath.

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease

Retrieved on: 
Monday, January 9, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, IND, Disease, Cardiomyopathy, New York University Grossman School of Medicine, Danon disease, Toxicology, ARVC, Pharmacology, AAV, Natural history, ACM, FA, Arrhythmia, Degenerative disease, FDA, NYHA, Biomarker, Fanconi anemia, Medication, Genetics, New York Heart Association Functional Classification, Conference, Autosome, Adolescence, BLA, Survival, PVC, Patient, Arrhythmogenic cardiomyopathy, Heart failure, HIV disease progression rates, Mortality, CGMP, NYU, GMP, BNP, Pharmaceutical industry, Vaccine, PKP2, EU

We have shared these updates with the FDA as part of our pivotal Phase 2 study design discussions.

Key Points: 
  • We have shared these updates with the FDA as part of our pivotal Phase 2 study design discussions.
  • “Lastly, I am pleased to note an extension of our cash runway, which we expect to fund operations through 2024.
  • Available treatments fail to address the underlying genetics and disease biology and do not alter disease progression.
  • A live audio webcast of the presentation is available under “Events” in the Investors section of the Company’s website at https://ir.rocketpharma.com .

United States Hereditary Genetic Testing Market Analysis and Forecasts, 2022-2032 with Laboratory Corporation of America Holdings, Quest Diagnostics, & F. Hoffmann-La Roche Dominating - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Health, Genetics, Genetic testing, LabCorp, Parkinson's disease, Heredity, Brain, Ascension, Benchmarking, Illumina, Inc., LRRK2, Epidemiology, Partnership, Genetic, Growth, Qiagen, Drug discovery, Prevalence, Software, Research, Cancer, Agriculture, Pharmaceutical industry, Vaccine, Audit, Medical imaging

Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • Among application area, all the four sub-segments constitute an almost equal share in the U.S. hereditary genetic testing market.
  • Hereditary Genetic Testing Market
    On 3 October 2022, Laboratory Corporation of America Holdings concluded the transactions, establishing a long-term laboratory connection with Ascension.
  • The following companies had a total market share of over 25% in 2021 and were highly active in the U.S. hereditary genetic testing market:

Global Genetic Diagnostics Market Report 2023: Rising Number of Genetic Disorders Stimulates Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Health, Genetics, Disease, Genetic testing, International System for Human Cytogenetic Nomenclature, Prenatal development, QIAGEN, Cancer, Parent, Porter W Anderson Jr., Government, Porter's five forces analysis, Thermo Fisher Scientific, Competition, Cytogenetics, Illumina, Inc., Organization, Growth, Abbott Laboratories, Patient, SWOT, Mortality, Quest Diagnostics, Myriad Genetics, Hoffmann-La Roche, USD, Genetic disorder, COVID-19, Danaher Corporation, Pharmaceutical industry, Medical device, Application

The genetic diagnostics market is driven by a rising number of genetic disorder cases.

Key Points: 
  • The genetic diagnostics market is driven by a rising number of genetic disorder cases.
  • The report analyses the Genetic Diagnostics Market By Type (Predictive and Presymptomatic Testing, Diagnostics Testing, Prenatal and Newborn Testing, Pharmacogenetic Testing, Other Application).
  • The report analyses the Genetic Diagnostics Market By Application (Cancer Diagnosis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, Other Application).
  • The Global Genetic Diagnostics Market has been analysed by countries (United States, Canada, Germany, UK, France, Spain, China, Japan, India, Australia).

Cellworks Expands Into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets

Retrieved on: 
Monday, January 9, 2023
Software, Research, General Health, Pharmaceutical, Data Management, Oncology, Technology, Genetics, Clinical Trials, Science, Biotechnology, Health, Other Science, Molecule, Toxicity, Publication, StoneX Group Inc., AML, NGS, Daly, Biomarker, MD, Norwich Pharma Services, Drug, Drug development, Biosimulation, Patient, UnitedHealth Group, Cancer, Immortalised cell line, Clinical trial, CBM, Third-generation sequencing, Pharmaceutical industry, Medical imaging, Management

“But in many instances, the Cellworks Platform has the ability to predict the human clinical response to drug candidates years earlier than traditional development pipelines.

Key Points: 
  • “But in many instances, the Cellworks Platform has the ability to predict the human clinical response to drug candidates years earlier than traditional development pipelines.
  • Cellworks biosimulation results may provide guidance for additional indications to target for clinical development.
  • “We are well-positioned to enhance clinical markets by addressing the significant unmet needs in both precision pharma and personalized oncology.
  • I am looking forward to advancing Cellworks mission to improve patient outcomes through precision drug development and personalized therapy selection.”

Athersys Provides MultiStem Clinical Update

Retrieved on: 
Monday, January 9, 2023
Stem Cells, Biotechnology, Manufacturing, Health, Pharmaceutical, Other Science, Research, Other Manufacturing, Genetics, Science, Clinical Trials, Ischemia, Internet, EMA, McGovern Medical School, European Medicines Agency, University, Blood, Tissue, TPA, Mitsubishi, World Stroke Organization, Autoimmunity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Regenerative medicine, Nature Reviews Neurology, Safety, University of Texas Health Science Center at Houston, FDA, Trauma, Inflammation, 3D, Department of Defense Serum Repository, Partnership, Houston Methodist Hospital, Conference, Protein, Central nervous system, FAHA, Resuscitation, Mitsubishi UFJ Financial Group, Weill Cornell Medicine, Food, Patient, Children's Memorial Hermann Hospital, State, Memorial Hermann–Texas Medical Center, Stroke, Trauma Center, Trauma center, MTEC, Pharmaceutical industry, Vaccine, Neurology

Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2).

Key Points: 
  • Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2).
  • MultiStem is a proprietary off-the-shelf stem cell product in late-stage clinical trials for acute ischemic stroke, as well as trauma and other inflammatory conditions.
  • MASTERS-2 is a company-sponsored Phase 3 randomized, double-blind, placebo-controlled trial evaluating MultiStem for the treatment of acute ischemic stroke.
  • Athersys’ enthusiasm about MultiStem for the treatment of ischemic stroke has been bolstered by results from completed clinical trials, and we look forward to providing updates on MASTERS-2 after we engage with regulatory authorities during the first quarter of 2023,” stated Dan Camardo, Chief Executive Officer of Athersys.

bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Bluebird bio, Bluebird, Medicaid, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PRV, SCD, Environment, Conference, Pharmacy, Food, BLA, Webcast, Patient, Sale, Sickle cell disease, QTC, Pharmaceutical industry, Health insurance

bluebird bio, Inc. (Nasdaq: BLUE) (the Company) today announced updates to be presented at the 41st Annual J.P. Morgan Healthcare conference including commercial launch progress, 2023 program milestones and financial outlook.

Key Points: 
  • bluebird bio, Inc. (Nasdaq: BLUE) (the Company) today announced updates to be presented at the 41st Annual J.P. Morgan Healthcare conference including commercial launch progress, 2023 program milestones and financial outlook.
  • “In a dynamic and challenging environment, bluebird has hit all its operational milestones, including nearly simultaneous launches of two first-in-class gene therapies, ZYNTEGLO and SKYSONA.
  • Presentation at the 2023 J.P. Morgan Healthcare Conference
    Andrew Obenshain, chief executive officer, bluebird bio, will present a corporate update on Thursday, January 12, at 7:30 a.m. PT.
  • A replay of the webcast will be available on the bluebird bio website for 30 days following the event.

Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones

Retrieved on: 
Monday, January 9, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, IND, Cardiovascular disease, Non-Hodgkin lymphoma, PHH, Lilly, University, Kidney disease, Tissue, Primate, OTC, HBV, CMC, Duchenne muscular dystrophy, Trial of the century, Vivo, Novartis, LNP, Safety, Degenerative disease, FDA, Data, Gene editing, Hepatitis B virus, Completeness, Partnership, Stem cell, DMD, CAR, Hepatocyte, Patient, Mouse, Chromosomal translocation, NHL, Precision, CTA, PH1, FH, Sickle cell disease, Infant, Pharmaceutical industry, Risk management, Vaccine, Antibiotics

Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today reported on its significant accomplishments in 2022 and announced its corporate priorities and anticipated clinical development and research milestones for 2023.

Key Points: 
  • Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today reported on its significant accomplishments in 2022 and announced its corporate priorities and anticipated clinical development and research milestones for 2023.
  • “In 2022, we advanced our corporate priorities strengthening the company and made significant progress with our clinical programs and research pipeline.
  • Progress azer-cel to decision point for Phase 2 trial in non-Hodgkin lymphoma (NHL) subjects who have relapsed following autologous CAR T treatment.
  • Present CAR T clinical update in the first quarter of 2023, based on patient accrual and follow-up.